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Introduction: Concurrent hairy cell leukemia (HCL) and chronic lymphocytic leukemia 
(CLL) is rare; management is inadequately described in the literature.
Methods: Retrospective chart review and clinical follow-up.
Results: Five patients are described. The first patient developed synchronous HCL and 
CLL and was treated with rituximab for 13 months with HCL in remission and stable 
CLL. The second patient developed HCL and was treated with cladribine. His disease 
recurred 7 years later which was retreated with cladribine. Seven years later, he devel-
oped asymptomatic CLL. The third patient developed CLL, managed expectantly, then 
developed HCL 10  months later, and was treated with cladribine. Although his HCL 
went into remission, there was a slow redevelopment of CLL for which expectant man-
agement was done. The fourth patient developed concurrent CLL and HCL, received 
cladribine, with subsequent development of worsening abdominal lymphadenopathy 
and was lost to follow-up. The last patient developed concurrent HCL and CLL and was 
also diagnosed with lung adenocarcinoma; this patient was also lost to follow-up.
Conclusion: The development of concurrent HCL and CLL may indicate a common 
origin. Patients with HCL may subsequently develop CLL, thus mimicking a relapse of 
HCL. Therapy requires individualized approach including watchful waiting in asymptom-
atic cases. Rituximab may be useful to treat both disorders simultaneously.
Keywords: hairy cell leukemia, chronic lymphocytic leukemia, cladribine, rituximab, fludarabine
INtRoDUCtIoN
This work was approved by the University of Nebraska Medical Center Institutional Review Board 
and Ethics Committee. Ethical approval was obtained for the study and all participants have con-
sented to participate in the research project and to the publication of their personal communication. 
All research participants signed written informed consent in accordance with the Declaration of 
Helsinki.
tabLe 1 | Clinical characteristics of the study population.
Case age at first 
diagnosis
First 
diagnosis
CbC LDH (U/L) 
(normal 
range)
Cytogenetics treatment outcome Follow-up 
(months)
1 69 HCL, CLL WBC 20.8 (Ly 79%) 100 (98–192) Deletion of 7q31 Rituximab HCL in remission; stable CLL 58
Hgb 15.8
Plt 108
2 49 HCLa WBC 11.1 (Ly 71%) 563 (313–618) Trisomy 12 Cladribine HCL relapse; development of CLL 250
Hgb 13.9
Plt 113
3 47 CLLb WBC 3.1 – Deletion of 13q Cladribine HCL in remission; slow redevelopment 
of CLL with expectant management 
thereafter
79
Hgb 12.3
Plt 52
4 43 HCL, CLL WBC 4.1 (Ly 34%) 130 (98–192) Trisomy 12, partial 
deletion of 5′ 
telomeric 14q32 
locus
Cladribine Worsening lymphadenopathy; lost to 
follow-up
13
Hgb 14.1
Plt 94
5 79 HCL, CLL WBC 9.0 (Ly 68%) – None Nonec Transfer to an outside facility 1
Hgb 18.7
Plt 102
CBC, complete blood count; HCL, hairy cell leukemia; CLL, chronic lymphocytic leukemia; WBCs, white blood cells (thousands of cells per microliter); Ly, lymphocytes; Hgb, 
hemoglobin (grams per deciliter); Hct, hematocrit; Plt, platelets (thousands of cells per microliter); SLL, small lymphocytic lymphoma.
aIn this patient, HCL relapsed after 7 years and was retreated with cladribine. The patient developed CLL 14 years after the initial diagnosis of HCL.
bIn this patient, CLL was diagnosed with HCL 10 months after initial diagnosis of CLL.
cThe patient was diagnosed with lung cancer and underwent therapy for lung cancer.
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Case 1
A 69-year-old Caucasian male, with a history of 35  pound 
weight loss, was found to have a white blood cell (WBC) count 
of 20.8 × 109/L, with 79% lymphocytes. His brother had died of 
chronic lymphocytic leukemia (CLL). Flow cytometric analysis 
revealed two distinct monoclonal B-cell populations. A pre-
dominant CD19+/CD20−/CD5+/CD23+/dim surface kappa+/
CD25−/CD103− population, consistent with CLL and the sec-
ond (bright CD20+/bright CD19+/CD11c+/CD25+/CD103+/
bright lambda+) smaller population, consistent with hairy cell 
leukemia (HCL). Bone marrow (BM) biopsy was predominantly 
involved by HCL, with focal involvement by CLL. Cytogenetic 
analysis showed a deletion of 7q31. He underwent four treat-
ments of weekly rituximab (375 mg/m2) followed by maintenance 
rituximab every 3 months for a total of 13 months. Two months 
after completion of treatment, flow cytometry of the peripheral 
blood showed involvement by the CLL cell population, but no 
evidence of HCL. He was then clinically monitored for CLL 
owing to a lack of symptoms and stable WBC counts between 10 
and 16 × 109/L. The patient developed papillary thyroid cancer 
51  months after initial diagnosis for which he had successful 
surgery. Fifty-eight months after initial diagnosis, CT chest was 
found to have multiple pulmonary and pleural nodules, and while 
further workup was underway, he was hospitalized with dyspnea 
and altered mental status and passed away (Table 1).
Case 2
A 49-year-old Caucasian female developed HCL treated with 
cladribine which led to remission. She relapsed 7 years later and 
was successfully retreated with cladribine. Seven years thereafter, 
she presented with cervical lymphadenopathy. WBC count was 
11.1 × 109/L with 71% lymphocytes. Biopsy of the lymph node 
revealed small lymphocytic leukemia (SLL) and a subsequent BM 
biopsy showed involvement by CLL/SLL occupying 10% of the 
BM space. At that time, HCL was not detected in the peripheral 
blood or BM biopsy. Cytogenetic analysis showed trisomy 12. She 
is being clinically followed up in our clinic and remains asymp-
tomatic and clinically stable at 82  months after CLL diagnosis 
(nearly 21 years after initial HCL diagnosis).
Case 3
A 49-year-old Caucasian male was referred for pancytopenia and 
spontaneous bruising. Complete blood count (CBC) showed a 
WBC count of 3.1 × 109/L and platelets of 52 × 109/L. A peripheral 
blood smear and BM biopsy performed at an outside institution 
were reportedly normal, but flow cytometry revealed a dim 
CD19+/CD20+/CD5+/CD23+/kappa+ monoclonal B-cell 
population, consistent with a monoclonal B-cell lymphocytosis 
of CLL phenotype. Cytogenetic analysis revealed 13q deletion. 
Clinical expectant management and close follow-up was insti-
tuted due to patient preference. Ten months later, he presented 
with febrile neutropenia. A peripheral blood smear at that time 
showed circulating lymphoma cells, morphologically consistent 
with simultaneous involvement by HCL and CLL. A subset of the 
neoplastic cells showed tartrate resistant acid phosphatase (TRAP) 
positivity. A BM biopsy showed diffuse involvement by HCL, and 
no evidence of involvement by CLL. The patient was treated with 
cladribine for a month with a repeat BM biopsy 2 months after 
completion showing resolution, and confirmed by normalization 
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of blood counts and flow cytometry. He was clinically followed 
up for the next 5.5 years, until he started developing thrombocy-
topenia (hemoglobin 13.0 g/dL, platelets 104 × 109/L, and WBC 
7.8 × 109/L). A BM biopsy showed simultaneous involvement by 
HCL and CLL (20 and 5% of the BM space, respectively). A 13q 
deletion was present. The patient was managed expectantly.
Case 4
A 43-year-old male with a family history of leukemia in his 
grandmother and multiple myeloma in his grandfather experi-
enced night sweats and left upper quadrant abdominal pain, and 
presented to an outside facility. A CBC showed monocytopenia, 
and peripheral smear showed rare atypical lymphoid cells, sug-
gestive of CLL. Flow cytometry of the peripheral blood showed 
a predominant population of mature B-cells (CD19+/CD20+/
CD5+/CD23+/moderate-density lambda+) and the second very 
small population (bright CD19+/bright CD20+/bright CD11c+/
CD25+/CD103+/moderate lambda+), consistent with HCL. BM 
biopsy then demonstrated HCL, involving 20% of the BM space 
and CLL, involving 1% of the BM space (Figure 1). Flow cytometry 
of the BM aspirate detected the two distinct monoclonal B-cell 
populations with similar immunophenotypic characteristics to 
that seen in the peripheral blood. Cytogenetic studies showed 
trisomy 12 and a partial deletion of the 5′ telomeric 14q32 locus. 
He was treated with 7 days of intravenous cladribine, resulting in 
remission of HCL. Just over a year later, he experienced abdomi-
nal swelling and right upper quadrant abdominal pain, with 
computed tomography revealing retroperitoneal and mesenteric 
lymph nodes that were pathologically demonstrated to be HCL. 
The patient was subsequently lost to follow-up.
Case 5
A 79-year-old Caucasian male presented with 1 year history of 
dry cough and a 15-pound weight loss. Chest imaging revealed 
multiple lung nodules, which were biopsied and showed adeno-
carcinoma. CBC showed WBC of 9.0 × 109/L with 68% lympho-
cytes and hemoglobin of 18.0  g/dL. Peripheral smear showed 
two distinct neoplastic populations. The majority of lymphocytes 
showed cytological features of CLL and were admixed with a 
few hairy cells. The BM aspirate showed a reverse pattern with 
the majority of cells having cytological and immunophenotypic 
features of HCL (diffuse interstitial infiltrate of strong CD20+/
CD5−/DBA-44+ B-cells). In addition, flow cytometry of the BM 
aspirate showed two distinct monoclonal B-cell populations, a 
CD19+/dim CD20+/dim CD5+/CD23+/dim kappa+ popula-
tion, consistent with CLL and a bright CD19+/bright CD20+/
CD11c+/CD25+/CD103+/bright kappa+ population, consistent 
with HCL. No cytogenetic abnormalities were detected. Given 
findings of multiple pulmonary nodules and borderline enlarged 
mediastinal lymph nodes, it was recommended that the patient 
undergo chemotherapy for lung cancer first. However, the patient 
was transferred to an outside facility.
baCKGRoUND
In this paper, we describe five patients with coexistence of 
HCL and CLL seen at our institution and focus on differential 
pathologic, immunophenotypic, and cytogenetic characteristics, 
as well as examine their treatment regimens and outcomes.
Chronic lymphocytic leukemia and HCL are chronic B-cell 
lymphoproliferative disorders with distinct morphologic 
features, immunophenotype, and clinical presentations. The 
diagnosis of CLL is usually based on the finding of lympho-
cytosis and the presence of a monotonous population of small 
lymphocytes with clumped chromatin and scant cytoplasm in 
the peripheral blood smear. These tumor cells express CD5, 
CD23, dim monotypic surface immunoglobulin, and dim 
CD20. Lymphadenopathy is frequent, and splenomegaly is seen 
in a relative minority of patients with CLL (1). Conversely, HCL 
presents with pancytopenia (or monocytopenia), splenomegaly, 
and opportunistic infections. Lymphadenopathy is unusual in 
HCL. Most patients do not present with lymphocytosis, but 
circulating intermediate-sized neoplastic lymphoid cells with 
characteristic “hairy” cytoplasmic projections are often present 
(2). The classic immunophenotypic profile of HCL consists 
of bright expression of CD19, CD20, CD22, and monotypic 
surface immunoglobulin and expression of CD103, CD25, 
CD11c, AnnexinA1, DBA.44, and cyclin D1 (usually weak). 
Additionally, all HCL cases will contain at least some cells with 
cytoplasmic TRAP positivity (1–6).
The association of HCL and CLL is considered to be rare (7), 
with prior experiences limited to a few case reports (7–10). It is 
increasingly being acknowledged that HCL can predispose to 
developing multiple types of secondary malignancies including 
non-Hodgkin lymphomas, possibly due to associated cancer 
susceptibility and/or treatment-related effects (11–13), although 
the etiology is debated (14). Although a high frequency of non-
Hodgkin lymphomas have been reported (12, 14), the occurrence 
of CLL as the second malignancy has only been reported by one 
study (12).
The presence of concurrent or metachronous CLL and HCL 
can predictably be problematic for clinicians given its rarity. 
Treatment can be a challenge, given relatively indolent courses 
for both malignancies and balancing it against the potential 
complications of therapy. Such treatment decisions are often left 
for a case-by-case basis, due to the need to gauge the overall 
clinical circumstance in deciding treatment and follow-up 
options.
DIsCUssIoN
Concurrent diagnosis of HCL and CLL has been rarely described 
in the literature; as a result, the characteristics, treatment options, 
and prognosis remain unclear. We characterize five patients seen 
at our institution that developed HCL and CLL including patho-
logic findings, management, and outcomes.
Our results are in many aspects both similar to and different 
from prior case reports. Gine et  al. described three patients 
with concurrent HCL and CLL, all of whom had two distinct 
monoclonal CD5+/CD23+ and CD11c+/CD25+ (and two 
with CD103+) B-cell populations. Two patients presented with 
features of HCL (splenomegaly and pancytopenia) and the 
diagnosis of CLL was made based on morphologic and immu-
nophenotypic assessment of the monoclonal B lymphocytes. 
FIGURe 1 | bone marrow (bM) biopsy of a case with synchronous chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (sLL) and hairy 
cell leukemia (HCL). (a–D) BM core biopsy specimen showing an abnormal lymphoid infiltrate with a diffuse growth pattern. The infiltrate is positive for CD20 (b), 
and negative for CD5 and CD23 [(C,D), respectively], consistent with involvement by HCL. The CLL infiltrate is focally present in the core biopsy (1% of the BM 
space; data not shown). (e) The corresponding flow cytometric analysis shows two distinct monoclonal populations: a CD20 dim+, CD5+, CD103−, CD11c−, 
lambda restricted CLL/SLL population (in blue) and a CD20 bright+, CD5−, CD103+, CD11c+, lambda restricted HCL population (in red). The HCL population is 
also positive for CD25 (data not shown).
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The third patient was found to have CLL, 1 year following the 
diagnosis of HCL. Cytogenetics was normal in two patients, 
whereas one patient had a t(1;19)(p35;q40) translocation. All 
three patients were initially treated with pentostatin, which led 
to remission of HCL. However, two out of three patients sub-
sequently exhibited progression of CLL and were treated suc-
cessfully with cladribine and fludarabine/cyclophosphamide/
mitoxantrone followed by autologous stem cell transplant, 
respectively (7).
Brown et  al. reported a 75-year-old man who developed 
metachronous HCL 17 years following diagnosis and treatment 
of CLL. The patient was initially treated with chlorambucil and 
prednisolone due to worsening night sweats, splenomegaly, 
and pancytopenia. However, pancytopenia persisted, and he 
underwent splenectomy. He was found to have both CLL and 
HCL in his BM 18  years following his initial diagnosis. Flow 
cytometric analysis revealed two distinct clonal lymphocytes; 
a low-frequency CD19+/CD5+/FMC7−/CD25−/dim surface 
immunoglobulin+ B-cell population consistent with CLL and a 
high-frequency FMC7+/CD25+/CD22+/CD5+/bright surface 
immunoglobulin+ B-cell population consistent with HCL. 
Interestingly, the HCL clone was also CD5+, a finding that has 
been reported previously (15). Subsequently, the patient was 
treated with alpha interferon, which resulted in remission and no 
evidence of recurrence at 19 months of follow-up (8).
Finally, Sokol and Agosti demonstrated two different mono-
clonal populations in the peripheral blood of an 83-year-old male, 
a dominant CD19+/CD20+/CD5+/CD23+ clone with lambda 
light chains, and a minor CD20+/CD11c+/CD25+/CD103+ 
clone with kappa restriction, consistent with concurrent CLL 
and HCL. Chlorambucil and prednisone yielded no response, 
and subsequent cladribine (one cycle) led to stable disease for 
6  months. Three cycles of fludarabine and cyclophosphamide 
yielded complete response for 5–7 months before severe anemia 
led to the discovery of CLL infiltration of the BM. He was then 
treated with eight weekly cycles of rituximab, which led to a 
complete response at 8 months follow-up (10).
The precise reason for coexistence of both CLL and HCL is 
unknown. Both HCL and CLL are chronic B cell lymphoprolif-
erative disorders that represent malignant transformations of B 
lymphocytes at different stages of a single differentiated pathway 
(8). Gene expression profiling studies have suggested that HCL 
patients may originate from post-germinal center memory 
B cells (16). Conversely, about 50% of CLL derive from post-
germinal center CD5+, CD27+, and memory B cells (7, 17). 
Transformations of CLL to B cell lymphoproliferative disorders 
such as large cell lymphoma and prolymphocytic leukemia are 
a well-recognized phenomenon. Similarly, there is also evidence 
that HCL can also evolve into higher grade lymphoma, much 
like the Richter’s transformation seen among patients with CLL 
(18). Patients with CLL have impaired immune surveillance 
that makes them prone to develop second neoplasms. Similarly, 
patients with HCL have been found to have an excess risk of 
developing hematologic malignancies, particularly Hodgkin 
and non-Hodgkin lymphomas (12). Presence of the same 
immunoglobulin gene rearrangements in two different clonal 
population (HCL and CLL) may suggest a common precursor 
origin and has been reported before (7, 9). However, other 
reported cases presented with two different immunoglobulin 
rearrangements, suggesting a different clonal origin (7, 8, 
10). Moreover, emerging data from a recent study emphasize 
sequencing of the IGHV-D-J and BRAF V600E loci (19). It is 
important to note that leukemic cells from CLL patients, upon 
exposure to phorbol ester, acquire the phenotype of hairy cells 
(20). In addition, chronic B cell lymphoproliferative disor-
ders with features intermediate between HCL and CLL have 
described in the literature (21, 22). These observations suggest 
that HCL and CLL may be clonal disorders at different stage of 
maturation of the same lymphocyte.
Our case series includes patients with both synchronous 
(patients 2, 3, 4, and 5) and metachronous (patient 1) exist-
ence of HCL and CLL. Most of the prior reports have included 
patients with coexistence of HCL and CLL (7, 10), although both 
HCL developing among CLL patients (8) and CLL developing 
among HCL patients (7), have been described. Hisada et al. had 
earlier reported 5 cases of secondary CLL among 3,104 patients 
with HCL in the Surveillance, Epidemiology, and End Results 
Program database (12). Similarly, population-based studies have 
demonstrated an increased risk of secondary hematological 
malignancies, particularly lymphomas, among patients with a 
history of CLL. However, an increased risk of HCL has not been 
specifically evaluated in these studies (23, 24).
A common theme among patients with synchronous tumors is 
that peripheral blood flow cytometry often reveals CLL to be the 
dominant clone, whereas HCL is often dominant on BM studies. 
Brown et al. suggest that the dominance of HCL in BM may be 
reflective of a growth advantage of HCL over CLL. Furthermore, 
the authors hypothesize that this could be due to differential rates 
of proliferation or apoptosis, a secondary immunodeficiency state 
allowing emergence and progression of the second lymphopro-
liferative disorders and inhibitory cytokine production by HCL 
cells (8). In light of these observations, it is interesting to note that 
in our series, most patients required treatment for HCL, whereas 
CLL was often asymptomatic and slowly progressive and could 
be followed up alone.
The diagnosis of simultaneous CLL and HCL based on 
morphology alone can be challenging. In our case series, HCL 
was the predominant component in the BM. Flow cytometry 
and immunohistochemical stains were required to highlight the 
more subtle CLL component. The opposite can also be the case 
since it is well known that HCL infiltrates can be subtle, especially 
when they show an interstitial growth pattern. Given the distinc-
tive immunophenotype of HCL and CLL, flow cytometry and 
immunohistochemistry are invaluable tools in the simultaneous 
diagnosis of these entities. However, since it is well known that 
HCL is associated with increased reticulin fibrosis and often 
results in a “dry tap”; flow cytometry of the BM may not always 
be available (25). In these cases, concurrent flow cytometry of 
the peripheral blood can be helpful in identifying the distinct 
populations. Additionally, a lymph node biopsy can confirm the 
diagnosis of CLL.
Though our approach to treatment in these patients centered 
around cladribine and/or rituximab, other reports have demon-
strated acceptable results with pentostatin (7), alpha-interferon 
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(8), and fludarabine/cyclophosphamide followed by rituximab 
(10). In light of previous case reports demonstrating failure 
sometimes after multiple chemotherapy regimens, it is note-
worthy in our analysis that simple expectant management of 
select patients resulted in long-term survival without clinical 
consequence.
CoNCLUsIoN
We report our institutional experience on five patients with 
coexistence of HCL and CLL, along with a review of previously 
reported cases. Concurrence of HCL and CLL may suggest an 
underlying relationship, and these two malignancies possibly rep-
resent clonal disorders at different stage of maturation of the same 
lymphocyte. Our experience suggests a variable presentation, 
chronology, and a need to tailor treatment strategy based on 
relative activity among these two diseases.
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